{"schema_version":"secwatch.filing_event.v1","accession":"0001789769-24-000100","form_type":"8-K","ticker":"TIL","cik":"0001789769","company_name":"Instil Bio, Inc.","filed_at":"2024-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.640357+00:00","generated_at":"2026-05-30T01:01:32.359853+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Instil Bio Q3 net loss $3.54/sh; cash $122.9M; licensed PD-L1xVEGF bispecific SYN-2510","bullets":["Licensed SYN-2510 (PD-L1xVEGF bispecific) and SYN-27M (CTLA-4 antibody) from ImmuneOnco for global ex-China rights.","Clinical data update for SYN-2510 monotherapy in China expected 1H 2025; Phase 1b/2 combo in NSCLC late 2024, TNBC 1H 2025 in China.","U.S. study of SYN-2510 in NSCLC targeted to start 2H 2025.","Cash, equivalents & securities $122.9M as of Sept 30, 2024 (down from $175.0M Dec 31, 2023); cash runway beyond 2026.","Q3 2024 net loss $3.54 per share vs $10.37 in Q3 2023; non-GAAP loss $2.55 vs $2.53."],"urls":{"canonical":"https://secwatch.observer/filing/0001789769-24-000100","json":"https://secwatch.observer/filing/0001789769-24-000100.json","markdown":"https://secwatch.observer/filing/0001789769-24-000100.md","text":"https://secwatch.observer/filing/0001789769-24-000100.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789769/000178976924000100/0001789769-24-000100-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789769/000178976924000100/til-20241113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:01:32.359853+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}